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ABSTRACT* 
Background: Therapeutic drug monitoring (TDM) makes 
use of serum drug concentrations as an adjunct to 
decision-making. Preliminary data in our hospital showed 
that approximately one-fifth of all drugs monitored by TDM 
service were gentamicin.  
Objective: In this study, we evaluated the costs 
associated with providing the service in patients with 
bronchopneumonia and treated with gentamicin.  
Methods: We retrospectively collected data from medical 
records of patients admitted to the Hospital Universiti 
Sains Malaysia over a 5-year period. These patients were 
diagnosed with bronchopneumonia and were on 
gentamicin as part of their treatment. Five hospitalisation 
costs were calculated; (i) cost of laboratory and clinical 
investigations, (ii) cost associated with each gentamicin 
dose, (iii) fixed and operating costs of TDM service, (iv) 
cost of providing medical care, and (v) cost of hospital stay 
during gentamicin treatment. 
Results: There were 1920 patients admitted with 
bronchopneumonia of which 67 (3.5%) had TDM service 
for gentamicin. Seventy-three percent (49/67) patients 
were eligible for final analysis. The duration of gentamicin 
therapy ranged from 3 to 15 days. The cost of providing 
one gentamicin assay was MYR25, and the average cost 
of TDM service for each patient was MYR104. The 
average total hospitalisation cost during gentamicin 
treatment for each patient was MYR442 (1EUR approx. 
MYR4.02).  
Conclusion: Based on the hospital perspective, in 
patients with bronchopneumonia and treated with 
gentamicin, the provision of TDM service contributes to 
less than 25% of the total cost of hospitalization. 
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INTRODUCTION 
Therapeutic drug monitoring (TDM) is defined as 
the measurement made in the laboratory of a 
parameter that, with appropriate interpretation, will 
directly influence prescribing procedures.1 TDM 
service comprises of measuring drug concentration, 
generating individual patient’s pharmacokinetic 
data, and interpreting such data together with the 
patient’s clinical conditions to optimise his/her drug 
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therapy. Since the early 1970s, it has been used to 
individualise drug therapy in patients on selected 
drugs with a narrow therapeutic index and wide 
pharmacokinetic variability like antiepileptics, 
aminoglycosides, and digoxin. TDM is also useful in 
cases where patient drug compliance is 
questionable, and where drug toxicity is suspected.  
To be meaningful, drug concentration must be 
available in a timely manner and commercially 
available immunoassays offer the most convenient 
method of drug analysis. However, the cost of 
performing drug assays especially in a developing 
country puts a constraint on a hospital’s budget.2,3 
In this era of cost-conscious healthcare 
environment, the pressure is on TDM practitioners 
to maintain a cost-effective service. However, 
studies evaluating costs associated with providing 
TDM services are not that common. Earlier report 
shows that out of 247 TDM studies conducted over 
a 20-year period, only 8% incorporated 
pharmacoeconomic analysis.4 Many of these 
pharmacoeconomic studies of TDM were conducted 
on aminoglycosides antibiotics.5 In a more recent 
analysis, Touw et al.6 concluded TDM is cost-
effective only for aminoglycosides, whereas TDM of 
vancomycin is cost-effective in selected patient 
populations only. Although TDM of other drugs is 
recommended, data on cost-effectiveness is still 
lacking.  
At Hospital Universiti Sains Malaysia (HUSM), TDM 
of aminoglycosides was started in the early 1980s. 
Early reports have shown that it had positive 
impacts on therapeutic concentrations and on 
prescribing of gentamicin in our setting but data on 
cost evaluation of the service are not available.7,8 
Preliminary TDM data from 2000 to 2005 showed 
that gentamicin represented 20% of all drugs 
monitored by the TDM service. In this article, we 
report the findings of a cost-evaluation of TDM 
service in patients diagnosed with 
bronchopneumonia and on gentamicin treatment. 
 
METHODS  
Study design 
This study employed a retrospective research 
design to perform a pharmacoeconomic evaluation 
of a hospital TDM service at the Hospital Universiti 
Sains Malaysia (HUSM). Data were collected 
retrospectively from medical records of eligible 
patients. The study was performed based on the 
hospital and health care provider perspectives. The 
study was performed at the HUSM, Malaysia. Data 
collection started in January and ended in March 
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2006. All aspects of the study protocol, including 
access to and use of the patient clinical information, 
were approved by the HUSM Administration 
Committee, chaired by the director of the hospital 
(Reference:HUSM/11/010).  
Population and sampling 
A computer generated list based on diagnosis code 
was provided by the Medical Records Office of 
HUSM. Medical records of adult patients admitted to 
the hospital from 2001 to 2005 with a diagnosis of 
bronchopneumonia infection were identified. The 
inclusion criteria for review were patients at least 18 
years of age, diagnosed as bronchopneumonia with 
proven or suspected gram-negative infection, 
admitted to the hospital for at least 72 hours, treated 
with gentamicin for at least 72 hours and had at 
least one gentamicin assay measurement.9,10 
Patients with existing renal impairment, who had 
history of aminoglycosides toxicity, with duration of 
gentamicin therapy less than 72 hours, or who 
received concurrent treatment with known 
nephrotoxic drugs were excluded.11,12 In addition, 
patients in whom gentamicin TDM service was 
requested after 72 hours of starting gentamicin 
treatment were excluded. Records of patients 
eligible for the study were then searched in the TDM 
database for details on gentamicin monitoring.  
Data collection procedure 
Data were collected for the following: patient 
demographics, duration of hospital stay, 
concomitant disease state, clinical and laboratory 
investigations, and the total number of serum 
concentration measurements done. The duration of 
gentamicin therapy, dosage regimen, duration of 
each regimen, concurrent antibiotics and 
medications were also determined. Nephrotoxicity 
was defined as an increase in serum creatinine by 
50% of its baseline.11,13 Duration of gentamicin 
therapy was calculated from duration the patient 
was hospitalised during gentamicin therapy.  
Data management and analysis 
Data on cost were obtained from the administrative 
office and bursary department of HUSM. TDM and 
gentamicin therapy data were obtained from the 
TDM laboratory and Department of Pharmacy. Five 
different hospitalisation costs were calculated for 
each patient; (i) cost of laboratory and clinical 
investigations during gentamicin therapy. These 
laboratory tests included blood profile, blood/sputum 
cultures, serum creatinine, electrolyte profile and 
chest X-rays. The total cost was calculated based 
on the hospital fee for each specific test multiplied 
by the number of tests done for each patient; (ii) 
cost associated with each gentamicin dose, which 
included the cost of gentamicin and disposables like 
syringes and alcohol swab; (iii) cost of providing 
TDM service, which included fixed costs (TDM 
laboratory space and laboratory equipment) and 
operating costs (i.e. time spent by the TDM team, 
reagents and consumables). Cost of TDM 
laboratory space was calculated by multiplying the 
area of the laboratory in square feet by the cost per 
square foot. TDM laboratory equipment included 
TDM instruments and furniture. The cost of 
laboratory equipment was calculated by subtracting 
the depreciated amount from the cost upon 
purchase by using 3% as a depreciation percentage 
rate.14 Gentamicin represented 20% of all tests 
performed, therefore, both the laboratory space and 
laboratory equipments costs were multiplied by 
0.20. The total operating cost was the summation of 
cost of reagents and consumables, and cost 
associated with the contribution of the TDM team. 
TDM team included the nurse, laboratory 
technician, and pharmacist. In our setting, nurses 
are responsible for blood collection, and the time 
spent for this activity was taken into consideration. 
Calculation of costs associated with the involvement 
of each of these health professionals was based on 
their basic monthly salaries and time spent 
performing the tasks; (iv) cost of providing medical 
care by doctors was calculated after taking into 
account their basic monthly salaries and the 
average duration spent for each patient visit. For 
nursing care time, it was determined from the time 
spent for performing clinical investigations such as 
measuring body temperature, and the time spent 
associated with the administration of gentamicin 
dose. Both costs were combined as cost of 
providing medical/nursing care; (v) cost of hospital 
stay during gentamicin treatment included the 
hospital room charges, and cost associated with 
non-medical services in the ward for the entire 
duration of gentamicin therapy. 
For the data obtained, we performed descriptive 
statistics and presented as mean (SD), median, 
frequency and percentage where appropriate. 
 
RESULTS  
There were 1,920 patients admitted to the hospital 
for chest infection and bronchopneumonia over the 
five-year period. Figure 1 shows how selection was 
made based on the selection criteria. Sixty-seven 
patients were diagnosed with bronchopneumonia 
and at the same time provided with the TDM service 
for gentamicin. Only 49 patients were eligible for 
further analysis. Patients age ranged from 18 to 77 
years old (median 42 years). Thirty-seven patients 
were male and 12 patients female. Ninety-six 
percent of patients were Malay. The study was not 
able to report how many of the 1,920 patients were 
on gentamicin.  
All patients received conventional multiple daily 
dosing of gentamicin. The average dose was found 
to be 241.8 (SD=57.5) mg/day (range: 120 to 375 
mg/day). All patients had other concurrent medical 
problems (eg. chronic obstructive pulmonary 
disease, diabetes, sepsis, hypertension). All except 
one patient were on concurrent antibiotics (e.g. 
ceftazidime, cloxacillin, erythromycin, penicillin G). 
Serum creatinine was measured in all patients 
before gentamicin therapy but this parameter was 
only available in 27 patients after therapy. Of these, 
none experienced an increase in serum creatinine 
over 50% from baseline (range: -42% to 45%). The 
mean duration of gentamicin therapy was 7.8 
(SD=2.9) days (range: 3 to 15 days).  
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Cost analysis 
Table 1 shows the distribution of costs associated 
with each of the components that made up the total 
cost of hospitalisation. The total cost of 
laboratory/clinical investigations and X-rays ranked 
the highest compared to other hospitalisation costs 
[Range: MYR42.00 to MYR336.00; (1 EUR approx. 
MYR4.02)]. In about 60% patients, the cost of 
laboratory/clinical investigations and X-rays was 
between MYR101.00 and MYR200.00.  
The cost of providing TDM service was obtained 
from fixed and operating costs. Based on data 
provided by the HUSM development office, the cost 
of TDM laboratory space was MYR9,800. The total 
cost of TDM equipment was estimated at 
MYR50,000. Overall, the total fixed cost was 
MYR12.90. The costs associated with time spent by 
the nurse, technician and pharmacist were 
MYR0.40, MYR0.75 and MYR1.30, respectively. 
Serum drug concentration was measured using 
fluorescence polarisation immunoassay (FPIA) 
technique (Abbott Lab., USA). This assay technique 
was used throughout the five-year period and there 
was no change in vendor. Each patient had an 
average of four gentamicin assays performed 
(range: 1 to 12 assays). The cost of TDM reagents 
and consumables associated with one gentamicin 
assay was found to be MYR10.12. Overall, the total 
operating costs associated with one gentamicin 
assay was MYR12.57. Therefore, the total cost of 
providing TDM service for one gentamicin assay 
was MYR25.47.  
The daily cost of medical/nursing care associated 
with time spent by doctor and nurse for each patient 
was found to be MYR6.25. In this cohort of patients, 
the cost of hospital stay (ie. room charges and non-
medical services) ranged from MYR9.00 to 
MYR45.00. It ranked the lowest and contributed to 
about 5% of the total hospitalisation cost. 
 
DISCUSSION 
TDM is widely available in Malaysia15 but this was 
the first study to look at the cost of providing the 
service from the hospital perspective. We have 
chosen to evaluate TDM of gentamicin in patients 
with bronchopneumonia because preliminary data 
showed that the most common drug monitored 
during that period was gentamicin (20%), and that 
among patients treated with gentamicin, the most 
common infection was bronchopneumonia (27%). 
Although nearly 2000 patients were hospitalised for 
bronchopneumonia over the five-year period, only 
49 adult patients satisfied the selection criteria. In 
this hospital, all patients on gentamicin will be 
Figure 1. Flowchart showing selection of patients for analysis.
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monitored for serum concentrations. Therefore, it 
could be deduced that only 67 patients received 
gentamicin during this period.  
In this study, we have attempted to quantify the 
monetary cost associated with the TDM service and 
how it contributes to the overall cost of 
hospitalisation during gentamicin therapy. Providing 
TDM service does not just involve the measurement 
of drug concentration. It is a multidisciplinary 
activity.16 It requires the collaboration among 
doctors, nurses, pharmacists and laboratory staff. 
Therefore, cost calculation of TDM service requires 
not only placing a value on the existing 
infrastructures (fixed costs) but also on the 
contributions of each of these health care staffs 
(operating costs).  
Several factors need to be considered when looking 
at the fixed cost associated with providing TDM 
service. As with other laboratories, the TDM 
laboratory has many other types of equipment, 
which are not directly related to the measurement of 
drug concentration but are essential for day-to-day 
running of the service. Each of these items has a 
different life expectancy. It is difficult to calculate the 
cost of each item individually due to its life 
expectancy. Accordingly, a constant value (i.e. 3%) 
was used as a depreciation rate for all these 
laboratory equipment.14 The application of this 
depreciation rate reduces the cost of each item 
depending on the year purchased. Therefore, the 
calculated cost of the laboratory equipment was 
found to be less by about 40% from the purchased 
cost (i.e. equals to 61% of the total purchased cost).  
For operating cost, it seems that the cost of 
reagents was substantially higher than cost 
associated with time spent by the TDM team. 
Fluorescence polarisation immunoassay (FPIA) 
technique used to measure drug concentration has 
a short turnaround time and is easy to run. 
However, its reagents are costly because Malaysia 
imports these TDM reagents from the USA through 
local vendors. Our results show that most patients 
were hospitalised for an average of about eight 
days and many had more than one assay 
measurement. Repeated measurement of TDM 
assays is a common practice in HUSM and this may 
contribute to increase in operating cost. HUSM TDM 
pharmacist often recommends doctors to repeat the 
assay after 72 hours. The pharmacist might have 
asked the assay to be repeated in order to ensure 
that therapeutic concentrations had been achieved 
based on dosing changes previously made. It is 
also likely that these repeat assays were carried out 
on the basis of the clinical status of the patient at 
the time.17,18  
The cost associated with administration of 
gentamicin dose made up 26% of total 
hospitalisation cost. In this study, all patients were 
treated with conventional dosing regimen of 
gentamicin. Providing multiple daily doses of 
gentamicin will increase the overall cost because 
each administration is associated with the use of 
several consumables. Unlike multiple daily dosing 
Table 1. Distribution of different hospitalization costs (N=49) 
Cost Type (MYR*) N (%) Mean MYR (SD) 
Contribution to 
total cost (%) 
Laboratory investigations and X-rays   150.80 (64.70) 34.1 
 ≤ 100 10 (20.4)   
 101-200 30 (61.2)   
 201-300 6 (12.2)   
 > 300 3 (6.1)   
Gentamicin dose  115.20 (46.40) 26.0 
 ≤100 20 (40.8)   
 101-200 26 (53.1)   
 > 200 3 (6.1)   
TDM service  103.96 (65.11) 23.5 
 0-50 1 (2.0)   
 51-100 21 (42.9)   
 101-150 15 (30.6)   
 151-200 6 (12.2)   
 >200 6 (12.2)   
Medical/Nursing Care  48.90 (18.10) 11.1 
 20-40 18 (36.7)   
 41-60 20 (40.8)   
 61-80 7 (14.3)   
 >80 4 (8.2)   
Duration of gentamicin therapy  23.50 (8.70) 5.3 
 ≤10 2 (4.1)   
 11-20 16 (32.7)   
 21-30 21 (42.9)   
 31-40 8 (16.3)   
 >40 2 (4.1)   
Total cost of hospitalization  442.48 (172.02)  100.0 
 100-200 3 (6.1)   
 201-300 7 (14.3)   
 301-400 14 (28.6)   
 401-500 9 (18.4)   
 501-600 8 (16.3)   
 >600 8 (16.3)   
*1 Euro approx. MYR4.02 
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regimen, single daily dosing regimen of gentamicin 
has widely used and has the advantages of 
lowering the cost of treatment.19  
Overall, our findings show that the total 
hospitalisation cost was dominated mostly by cost 
of imported reagents and consumables (eg. TDM 
reagents, reagents used for other laboratory 
investigations, and X-ray films), and cost of drug 
used (eg. gentamicin). On the other hand, labour 
costs (eg. TDM team and medical/nursing care) and 
hospital room charges contributed minimally to the 
overall cost of hospitalisation. There was a wide 
variation in the duration of hospitalisation seen 
among this cohort of patients. However, HUSM only 
imposed a nominal fee of MYR8.50 per day for 
inpatients. This may be the reason that cost 
associated with hospital stay was the lowest among 
other hospitalisation costs. 
In our setting, TDM service constituted about 24% 
of the total overall hospitalisation cost for the 
duration of gentamicin therapy. While labour costs 
are somewhat similar to other hospitals in the 
country, the cost associated with TDM assay may 
be different. Like other immunoassays, TDM assay 
reagents have expiration dates. Therefore, within 
that shelf life, there is a higher likelihood that these 
reagents will not be fully used especially in hospitals 
with low volume of TDM requests. As a result, the 
cost associated with the TDM service will increase.  
Since this was the first cost-analysis study carried 
out on TDM service in our setting, the findings could 
serve as a baseline data for future evaluation. Thus, 
any increase in cost contribution by the TDM 
service in the future should be carefully scrutinised. 
At the same time, we believe that there is still room 
for improvement to make the service more cost-
effective. While the price of reagents and 
consumables is beyond the TDM pharmacist’s 
control, the judicious utilisation of this service like 
improvement in appropriate indication and sampling 
should be made a priority.  
This study has its limitations. The analysis was 
conducted only on a small number of patients, 
which may contribute to bias. Medical records were 
not fully computerized and might not contain 
complete data. Therefore, we could not completely 
rule out the possibility that certain data like 
laboratory investigations might be missing from the 
records although the tests were actually done. 
 
CONCLUSIONS 
In patients with bronchopneumonia and treated with 
gentamicin, the provision of TDM service 
contributes to less than 25% total cost of 
hospitalisation. It is imperative that the service is 
used judiciously to avoid unnecessary increase in 
cost in the future. 
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EVALUACIÓN DEL COSTE DE LA 
MONITORIZACIÓN SÉRICA DE GENTAMICINA 
EN UN HOSPITAL UNIVERSITARIO DE 
MALASIA 
 
RESUMEN 
Antecedentes: La monitorización sérica de 
medicamentos (TDM) utiliza las concentraciones séricas 
como un elemento para la toma de decisiones. Los datos 
preliminares de nuestro hospital indican que 
aproximadamente un quinto de todos los medicamentos 
seguidos por TDM fue la gentamicina. 
Objetivo: En este estudio evaluamos los costes asociados 
con la provisión del servicio en pacientes con 
bronconeumonía y tratados con gentamicina. 
Métodos: Recogimos retrospectivamente datos de las 
historias clínicas de los pacientes ingresados en el 
Hospital Universidad de Sains Malasia durante 5 años. 
Estos pacientes estaban diagnosticados con 
bronconeumonía y estaban con gentamicina como parte 
de su tratamiento. Se calcularon 5 costes de 
hospitalización: (i) costes del laboratorio y análisis 
clínicos, (ii) costes asociados con cada dosis de 
gentamicina, (iii) costes fijos y operativos del servicio de 
TDM, (iv) coste de proporcionar atención médica, y (v) 
costes de la hospitalización durante el tratamiento con 
gentamicina.  
Resultados: Hubo un total de 1920 pacientes ingresados 
con bronconeumonía de los que 67 (3,5%) tuvieron 
servicio de TDM para la gentamicina. El 73% (49/67) de 
los pacientes estaban incluidos en el análisis final. La 
duración del tratamiento de gentamicina osciló entre 3 y 
15 días. El coste de realizar cada prueba de gentamicina 
era de 25 MYR, y el coste medio del servicio de TDM 
por paciente fue de 104 MYR. El coste medio de 
hospitalización por paciente durante el tratamiento con 
gentamicina fue de 442 MYR (1 EUR aprox. 4.02 MYR). 
Conclusión: Desde la perspectiva hospitalaria, los 
pacientes con bronconeumonía tratados con gentamicina, 
la provisión del servicio de TDM contribuye menos del 
25% al total de costes de hospitalización. 
 
Palabras clave: Monitorización de medicamentos; 
Costes y Análisis de Costes; Servicio de Farmacia 
Hospitalario; Gentamicinas; Bronconeumonía; Malasia 
 
 
References 
 
1. Watson I, Potter J, Yatscoff R, Fraser A, Himberg JJ, Wenk M. Definition of therapeutic drug monitoring. Ther Drug 
Monit. 1997;19(2):125.  
2.  Gogtay NJ, Kshirsagar NA, Dalvi SS. Therapeutic drug monitoring in a developing country: an overview. Br J Clin 
Pharmacol. 2001;52(Suppl 1):103S-108S. 
3.  Setiabudy R. Therapeutic drug monitoring: focus on conditions in Indonesia. Acta Med Indones. 2011;43(3):208-211. 
Ibrahim MI, Abdelrahim HE, Ab Rahman AF. Cost evaluation of therapeutic drug monitoring of gentamicin at a 
teaching hospital in Malaysia. Pharmacy Practice 2014 Jan-Mar;12(1):372. 
www.pharmacypractice.org (ISSN: 1886-3655) 6
4.  Schumacher GE, Barr JT. Economic and outcome issues for therapeutic drug monitoring in medicine. Ther Drug Monit. 
1998;20(5):539-542. 
5.  Destache CJ. Use of therapeutic drug monitoring in pharmacoeconomics. Ther Drug Monit. 1993;15(6):608-610. 
6.  Touw DJ, Neef C, Thomson AH, Vinks AA; Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the 
International Association for Therapeutic Drug Monitoring and Clinical Toxicology. Cost-effectiveness of therapeutic 
drug monitoring: a systematic review. Ther Drug Monit. 2005;27(1):10-17. 
7.  Ismail R, Sarriff A, Abdul Rahman AF. Therapeutic drug monitoring for gentamicin in Hospital Universiti Sains Malaysia. 
Med J Malaysia. 1990;45(1):57-64. 
8.  Ismail R, Haq AH, Azman M, Rahman AF. Therapeutic drug monitoring of gentamicin: a 6-year follow-up audit. J Clin 
Pharm Ther. 1997;22(1):21-25. 
9.  Saunders NJ, Adams DJ, Lynn WA. A prospective laboratory-based audit of gentamicin use and therapeutic monitoring. 
J Antimicrob Chemother. 1995;36(4):729-736. 
10. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an 
aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 
1999;43(7):1549-1555. 
11. Ho KK, Thiessen JJ, Bryson SM, Greenberg ML, Einarson TR, Leson CL. Challenges in comparing treatment outcome 
from a prospective with that of a retrospective study: assessing the merit of gentamicin therapeutic drug monitoring in 
pediatric oncology. Ther Drug Monit. 1994;16(3):238-247. 
12. Slaughter RL, Cappelletty DM. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug 
monitoring. Pharmacoeconomics. 1998; 14: 385-394.  
13. Rougier F, Ducher M, Maurin M, Corvaisier S, Claude D, Jelliffe R, Maire P. Aminoglycoside dosages and 
nephrotoxicity: quantitative relationships. Clin Pharmacokinet. 2003;42(5):493-500. 
14. Goldhaber-Fiebert JD, Denny LE, De Souza M, Wright TC, Kuhn L, Goldie SJ. The costs of reducing loss to follow-up in 
South African cervical cancer screening. Cost Eff Resour Alloc. 2005;3:11. 
15. Ab Rahman AF, Abdelrahim HEA, Mohamad Ibrahim MI. A survey of therapeutic drug monitoring services in Malaysia. 
Saudi Pharm J. 2013;21(1):19-24. doi: 10.1016/j.jsps.2012.01.002 
16. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52(Suppl 1):5S-10S. 
17. Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical 
Biochemistry. Clin Chem. 1998;44(5):1129-1140. 
18. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 
2001;52(Suppl 1):35S-43S. 
19. Martin JE. Commentary: once-daily aminoglycoside dosing: where are we now? J Crit Care. 2003;18(2):113-114. 
 
 
